NCT02011724Unknown4 期
An Open Label, Multi Center, Post Marketing Study Of Pain And Quality Of Life Outcomes In Subjects With a Single Painful Venous Leg Ulcer Treated With Apligraf®
适应症
试验速览
- 阶段
- 4 期
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- Percent reduction in maximum VLU-related pain at Week 5
研究概览
简要总结
The objective of the study is to demonstrate that treatment with Apligraf reduces venous leg ulcer (VLU)-related pain and improves the quality of life (QOL) of patients with a painful VLU.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is a minimum of 18 years of age.
- •Subject has read, understood, and signed an Institutional Review Board (IRB)-approved Informed Consent Form (ICF).
- •Subject is able and willing to follow study procedures and instructions.
- •Subject reports moderate VLU-related pain (defined as ≥4 based on maximum pain level over preceding 24 hours) on numeric rating scale (NRS) at both Week -2 and Day 0).
- •Subject has a partial or full-thickness VLU between 1-60 cm2 and 1-36 months duration, which, in the opinion of the Investigator, has not adequately responded to conventional ulcer therapy.
- •Female subject of childbearing potential has a documented negative urine pregnancy test.
- •Subject (male or female) agrees to use highly effective methods of contraception for the duration of the study.
排除标准
- •Subject has more than 1 VLU.
- •Female subject who is lactating.
- •Subject with significant or severe non VLU-related chronic pain which, in the Investigator's opinion, would impact subject's ability to evaluate their VLU-related pain. Subject with non-VLU-related chronic pain must be on a stable pain medication regimen and must, in the Investigator's opinion, not be anticipated to require a new pain medication for the chronic pain condition during the course of the study.
- •Subject is not willing to discontinue the use of topical analgesics at the VLU (topical anesthetic is permitted for debridement).
- •Subject who has arterial disease, as determined by an ankle-brachial index (ABI), of <0.
- •Subject who has received an investigational drug, device, or biological/bioactive treatment within 30 days prior to study enrollment.
- •Subject who is scheduled to have a vascular intervention on the study extremity during the study.
- •Subject with a biopsy confirmed active malignancy at the VLU. Also, subject with any active malignancy not at the VLU, with the exception of squamous cell carcinoma or basal cell carcinoma.
- •Subject who is currently receiving, anticipates receiving, or has received, at any time within 30 days prior to Screening visit, topical corticosteroids at the VLU.
- •Subject has vasculitis, severe rheumatoid arthritis, and other collagen vascular diseases.
- •Subject has signs and symptoms of wound infection, cellulitis, or osteomyelitis at the VLU.
- •Subject has a VLU with an avascular wound bed.
- •Subject has a VLU with exposed bone, tendon, or fascia.
- •Subject has other wounds (DFU, surgical, etc.) on the same limb as the VLU.
- •Subject has a known hypersensitivity to bovine collagen or to the components of the Apligraf agarose shipping medium.
- •Subject previously treated with Apligraf, or any other cell or tissue-based product at the VLU within 30 days of the Screening visit.
- •Subject who, in the opinion of the Investigator, has a history of alcohol or substance abuse within the previous year that could interfere with study compliance (eg, inability to attend scheduled study visits).
- •Subject, who in the opinion of the Investigator, for any reason other than those listed above, will not be able to complete the study per protocol.
结局指标
主要结局
Percent reduction in maximum VLU-related pain at Week 5
时间窗: Day 0 - Week 5
Based on the maximum pain levels during the preceding 24 hours
次要结局
- Reduction on SF-12v2 - Pain Enhanced Health Survey at Week 5(Day 0 - Week 5)
- Reduction in class and/or dose of VLU-related pain medications at Week 5(Day 0 - Week 5)
- Reduction in maximum VLU-related pain at 48 hours following initial Apligraf application(Day 0 - 48 hours after Apligraf application)
- Reduction on Cardiff Wound Impact Schedule (CWIS) at Week 5(Day 0 - Week 5)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
不适用
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.WoundsWound of SkinWound LegVenous Leg UlcerFoot WoundDiabetic Foot UlcerNCT05588583Molnlycke Health Care AB68
终止
3 期
Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)Epidermolysis Bullosa, JunctionalEpidermolysis Bullosa DystrophicaNCT00587223Organogenesis1
招募中
不适用
A Clinical Investigation to Follow the Progress of Exuding Chronic Venous Leg Ulcers Using a Non-Bordered Foam DressingWoundsWound of SkinWound LegVenous Leg UlcerNCT05608317Molnlycke Health Care AB20
已完成
2 期
Riociguat in Scleroderma Associated Digital UlcersDigital UlcersSclerodermaNCT02915835Dinesh Khanna, MD, MS17
终止
3 期
Apligraf Versus Standard Therapy in the Treatment of Diabetic Foot UlcersDiabetic FootNCT00512538Organogenesis82